BRCA1 and breast cancer: For example, the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib induces enhanced cytotoxicity in breast cancer cells that harbor BRCA1/2 mutations, as their endogenous DNA damage repair systems are suppressed by both BRCA1 inactivation and PARP inhibition.